{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:01:48Z","timestamp":1793325708970,"version":"4.5.0"},"reference-count":108,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:p>Thrombotic microangiopathy (TMA) is a syndrome of microangiopathic hemolytic anemia and thrombocytopenia with end-organ dysfunction. Although the advent of plasma exchange, immunosuppression, and complement inhibition has improved morbidity and mortality for primary TMAs, the management of secondary TMAs, particularly drug-induced TMA, remains less clear. TMA related to cancer drugs disrupts the antineoplastic treatment course, increasing the risk of cancer progression. Chemotherapeutic agents such as mitomycin-C, gemcitabine, and platinum-based drugs as well as targeted therapies such as antiangiogenesis agents and proteasome inhibitors have been implicated in oncotherapy-associated TMA. Among TMA subtypes, drug-induced TMA is less well-understood. Treatment generally involves withdrawal of the offending agent and supportive care targeting blood pressure and proteinuria reduction. Immunosuppression and therapeutic plasma exchange have not shown clear benefit. The terminal complement inhibitor, eculizumab, has shown promising results in some cases of chemotherapy-associated TMA including in re-exposure. However, the data are limited, and unlike in primary atypical hemolytic uremic syndrome, the role of complement in the pathogenesis of drug-induced TMA is unclear. Larger multicenter studies and unified definitions are needed to elucidate the extent of the problem and potential treatment strategies.<\/jats:p>","DOI":"10.34067\/kid.0000000000000061","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T17:30:07Z","timestamp":1674840607000},"page":"409-422","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":27,"title":["Chemotherapy-Associated Thrombotic Microangiopathy"],"prefix":"10.34067","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4843-2614","authenticated-orcid":false,"given":"Abinet M.","family":"Aklilu","sequence":"first","affiliation":[{"name":"Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5876-4802","authenticated-orcid":false,"given":"Anushree C.","family":"Shirali","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"5","key":"B1-20250823","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0002-9343(52)90022-3","article-title":"An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries","volume":"13","author":"Moschcowitz","year":"1952","journal-title":"Am J Med."},{"issue":"3","key":"B2-20250823","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"issue":"5","key":"B3-20250823","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/1097-0142(1971)28:5<1314::AID-CNCR2820280534>3.0.CO;2-D","article-title":"Renal toxicity in man treated with mitomycin C","volume":"28","author":"Liu","year":"1971","journal-title":"Cancer."},{"issue":"6","key":"B4-20250823","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry","volume":"7","author":"Lesesne","year":"1989","journal-title":"J Clin Oncol."},{"key":"B5-20250823","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.nephro.2017.01.016","article-title":"Thrombotic microangiopathies and antineoplastic agents","volume":"13","author":"Grang\u00e9","year":"2017","journal-title":"Nephrol Ther."},{"issue":"18","key":"B6-20250823","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-11-0804","article-title":"Thrombotic microangiopathy with targeted cancer agents","volume":"17","author":"Blake-Haskins","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"5","key":"B7-20250823","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/PAP.0000000000000122","article-title":"Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies","volume":"23","author":"Troxell","year":"2016","journal-title":"Adv Anat Pathol."},{"issue":"4","key":"B8-20250823","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine."},{"issue":"5","key":"B9-20250823","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B10-20250823","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and outcomes of thrombotic microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B11-20250823","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood."},{"issue":"11","key":"B12-20250823","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"B13-20250823","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1607-551X(09)70479-6","article-title":"Mitomycin C-induced renal insufficiency: a case report","volume":"19","author":"Wen","year":"2003","journal-title":"Kaohsiung J Med Sci."},{"issue":"6","key":"B14-20250823","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF01600261","article-title":"Glomerular tuft ballooning in mitomycin-C-induced renal impairment","volume":"420","author":"Shiiki","year":"1992","journal-title":"Virchows Arch A Pathol Anat Histopathol."},{"issue":"2","key":"B15-20250823","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br J Clin Pharmacol."},{"issue":"02","key":"B16-20250823","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution","volume":"71","author":"Glezerman","year":"2009","journal-title":"Clin Nephrol."},{"issue":"2","key":"B17-20250823","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000435807","article-title":"Improvement in gemcitabine-induced thrombotic microangiopathy with rituximab in a patient with ovarian cancer: mechanistic considerations","volume":"5","author":"Murugapandian","year":"2015","journal-title":"Case Rep Nephrol Dial."},{"issue":"1","key":"B18-20250823","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3123-6","article-title":"Rituximab to treat gemcitabine-induced hemolytic\u2013uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review","volume":"79","author":"Ritchie","year":"2017","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1","key":"B19-20250823","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12882-021-02386-y","article-title":"Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report","volume":"22","author":"Nishikubo","year":"2021","journal-title":"BMC Nephrol."},{"issue":"5","key":"B20-20250823","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/1097-0142(19890901)64:5<1017::AID-CNCR2820640508>3.0.CO;2-N","article-title":"Carboplatin-associated thrombotic microangiopathic hemolytic anemia","volume":"64","author":"Walker","year":"1989","journal-title":"Cancer."},{"issue":"2","key":"B21-20250823","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12032-013-0568-x","article-title":"Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report","volume":"30","author":"Iams","year":"2013","journal-title":"Med Oncol."},{"issue":"1","key":"B22-20250823","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13256-022-03309-7","article-title":"Oxaliplatin-induced thrombotic microangiopathy: a case report","volume":"16","author":"Saad","year":"2022","journal-title":"J Med Case Rep."},{"issue":"3","key":"B23-20250823","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1159\/000510307","article-title":"Oxaliplatin-induced thrombotic microangiopathy in a patient with stage IV gallbladder carcinoma: primary association or multiple hits?","volume":"13","author":"Fuentes-Lacouture","year":"2020","journal-title":"Case Rep Oncol."},{"issue":"1","key":"B24-20250823","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6904-6-5","article-title":"Hemolytic uremic syndrome following the infusion of oxaliplatin: case report","volume":"6","author":"Dahabreh","year":"2006","journal-title":"BMC Clin Pharmacol."},{"issue":"4","key":"B25-20250823","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/ckj\/sfaa101","article-title":"Complement C5 inhibition reverses bleomycin-induced thrombotic microangiopathy","volume":"14","author":"Salhi","year":"2021","journal-title":"Clin Kidney J."},{"issue":"1","key":"B26-20250823","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-101-1-41","article-title":"Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy","volume":"101","author":"Jackson","year":"1984","journal-title":"Ann Intern Med."},{"issue":"11","key":"B27-20250823","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med."},{"issue":"1","key":"B28-20250823","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13730-020-00504-7","article-title":"Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer","volume":"10","author":"Morimoto","year":"2021","journal-title":"CEN Case Rep."},{"issue":"5","key":"B29-20250823","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","article-title":"Thrombotic microangiopathy and anti-VEGF agents","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant."},{"issue":"24","key":"B30-20250823","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine."},{"key":"B31-20250823","first-page":"1","article-title":"Renal thrombotic microangiopathy associated with the use of bortezomib in a patient with multiple myeloma","volume":"2016","author":"Van Keer","year":"2016","journal-title":"Case Rep Hematol."},{"issue":"1","key":"B32-20250823","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12882-020-02226-5","article-title":"Two cases of carfilzomib\u2010induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma","volume":"22","author":"Rassner","year":"2021","journal-title":"BMC Nephrol."},{"issue":"3","key":"B33-20250823","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.transci.2016.03.002","article-title":"Carfilzomib: a cause of drug associated thrombotic microangiopathy","volume":"54","author":"Qaqish","year":"2016","journal-title":"Transfus Apher Sci."},{"issue":"6","key":"B34-20250823","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/ijlh.13682","article-title":"2021 update of the 2012 ICSH Recommendations for identification, diagnostic value, and quantitation of schistocytes: impact and revisions","volume":"43","author":"Zini","year":"2021","journal-title":"Int J Lab Hematol."},{"issue":"1","key":"B35-20250823","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ajh.10450","article-title":"Morphologic diagnosis of thrombotic thrombocytopenic purpura","volume":"75","author":"Burns","year":"2004","journal-title":"Am J Hematol."},{"issue":"11","key":"B36-20250823","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2215\/CJN.14721219","article-title":"Major bleeding and risk of death after percutaneous native Kidney biopsies: a French nationwide cohort study","volume":"15","author":"Halimi","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"02","key":"B37-20250823","first-page":"365","article-title":"Serum neutrophil gelatinase-associated lipocalin (NGAL) in patients with Shiga toxin mediated haemolytic uraemic syndrome (STEC-HUS)","volume":"111","author":"Vetter","year":"2014","journal-title":"Thromb Haemost."},{"key":"B38-20250823","doi-asserted-by":"crossref","first-page":"641427","DOI":"10.3389\/fimmu.2021.641427","article-title":"Biomarkers for early complications of endothelial origin after allogeneic hematopoietic stem cell transplantation: do they have a potential clinical role?","volume":"12","author":"Lia","year":"2021","journal-title":"Front Immunol."},{"issue":"4","key":"B39-20250823","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.2830500404","article-title":"Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C: vascular Endothelial Cell Injuries in RCFS Induced by Mitomycin C","volume":"50","author":"Nagaya","year":"1995","journal-title":"Am J Hematol."},{"issue":"1","key":"B40-20250823","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/asheducation-2005.1.403","article-title":"Acquired disorders of platelet function","volume":"2005","author":"Hassan","year":"2005","journal-title":"Hematology."},{"issue":"5","key":"B41-20250823","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.1985.3.5.723","article-title":"Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy","volume":"3","author":"Cantrell","year":"1985","journal-title":"J Clin Oncol."},{"issue":"2","key":"B42-20250823","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/1078155216628324","article-title":"Antineoplastic agents and thrombotic microangiopathy","volume":"23","author":"Garcia","year":"2017","journal-title":"J Oncol Pharm Pract."},{"issue":"1","key":"B44-20250823","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00873232","article-title":"Phase II trial of gemcitabine (2,2?-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas","volume":"12","author":"Casper","year":"1994","journal-title":"Invest New Drugs."},{"issue":"3","key":"B45-20250823","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1179\/1973947813Y.0000000122","article-title":"Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series","volume":"26","author":"Leal","year":"2014","journal-title":"J Chemother."},{"issue":"12","key":"B46-20250823","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.20290","article-title":"Gemcitabine-associated thrombotic microangiopathy","volume":"100","author":"Humphreys","year":"2004","journal-title":"Cancer."},{"issue":"7","key":"B47-20250823","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","article-title":"Gemcitabine-associated thrombotic thrombocytopenic purpura","volume":"8","author":"Zupancic","year":"2007","journal-title":"Lancet Oncol."},{"issue":"6","key":"B48-20250823","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00277-007-0429-9","article-title":"Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine","volume":"87","author":"De Smet","year":"2008","journal-title":"Ann Hematol."},{"issue":"5","key":"B49-20250823","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the BloodCenter of Wisconsin: drug-induced TMA","volume":"90","author":"Reese","year":"2015","journal-title":"Am J Hematol."},{"issue":"3","key":"B50-20250823","doi-asserted-by":"crossref","first-page":"439","DOI":"10.21873\/invivo.11080","article-title":"Thrombotic microangiopathy following chemotherapy with S-1 and cisplatin in a patient with gastric cancer: a case report","volume":"31","author":"Muto","year":"2017","journal-title":"In Vivo."},{"issue":"3","key":"B51-20250823","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.20516","article-title":"Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin","volume":"81","author":"Curtis","year":"2006","journal-title":"Am J Hematol."},{"issue":"10","key":"B52-20250823","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41409-018-0159-8","article-title":"High-dose carboplatin\/etoposide\/melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma","volume":"53","author":"Jodele","year":"2018","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"B53-20250823","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12882-021-02656-9","article-title":"Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literatures","volume":"23","author":"Yin","year":"2022","journal-title":"BMC Nephrol."},{"issue":"9","key":"B54-20250823","doi-asserted-by":"crossref","first-page":"E218","DOI":"10.1002\/ajh.25832","article-title":"Proteasome inhibitor\u2010associated thrombotic microangiopathy: a review of cases reported to the FDA adverse event reporting system and published in the literature","volume":"95","author":"Nguyen","year":"2020","journal-title":"Am J Hematol."},{"issue":"23","key":"B55-20250823","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1182\/bloodadvances.2018027532","article-title":"Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion","volume":"2","author":"Portuguese","year":"2018","journal-title":"Blood Adv."},{"issue":"12","key":"B56-20250823","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/ccr3.1214","article-title":"Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment","volume":"5","author":"Gosain","year":"2017","journal-title":"Clin Case Rep."},{"issue":"5","key":"B57-20250823","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfv059","article-title":"Thrombotic microangiopathy associated with proteasome inhibitors","volume":"8","author":"Lodhi","year":"2015","journal-title":"Clin Kidney J."},{"issue":"1","key":"B58-20250823","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-021-02434-3","article-title":"Fatal pulmonary tumour thrombotic microangiopathy in patient with ovarian adenocarcinoma: review and a case report","volume":"22","author":"Neverauskaite-Piliponiene","year":"2022","journal-title":"BMC Cardiovasc Disord."},{"issue":"1","key":"B59-20250823","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12882-020-1703-5","article-title":"Adrenocortical carcinoma complicated by renal thrombotic microangiopathy, a case-series","volume":"21","author":"de Nattes","year":"2020","journal-title":"BMC Nephrol."},{"issue":"1","key":"B60-20250823","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep."},{"key":"B61-20250823","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/ki.2008.615","article-title":"Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: distinct mechanisms of pathogenesis","volume":"75","author":"Tarr","year":"2009","journal-title":"Kidney Int."},{"issue":"1","key":"B62-20250823","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev.pathmechdis.3.121806.154311","article-title":"Pathogenesis of thrombotic microangiopathies","volume":"3","author":"Zheng","year":"2008","journal-title":"Annu Rev Pathol Mech Dis."},{"issue":"5","key":"B63-20250823","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ekir.2018.05.015","article-title":"Cobalamin C deficiency induces a typical histopathological pattern of renal arteriolar and glomerular thrombotic microangiopathy","volume":"3","author":"Lemoine","year":"2018","journal-title":"Kidney Int Rep."},{"issue":"6","key":"B64-20250823","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/bjh.16457","article-title":"Incidence, risk factors for and outcomes of transplant\u2010associated thrombotic microangiopathy","volume":"189","author":"Epperla","year":"2020","journal-title":"Br J Haematol."},{"issue":"1","key":"B65-20250823","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1076029615598221","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"22","author":"Elsallabi","year":"2016","journal-title":"Clin Appl Thromb Hemost."},{"issue":"04","key":"B66-20250823","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1055\/s-2007-1005110","article-title":"Prostacyclin and thrombotic microangiopathy","volume":"6","author":"Remuzzi","year":"1980","journal-title":"Semin Thromb Hemost."},{"issue":"6","key":"B67-20250823","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1055\/s-2005-925474","article-title":"Drug-induced thrombotic microangiopathy","volume":"31","author":"Zakarija","year":"2005","journal-title":"Semin Thromb Hemost."},{"issue":"6","key":"B68-20250823","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster","year":"2007","journal-title":"N Engl J Med."},{"issue":"3","key":"B69-20250823","doi-asserted-by":"crossref","first-page":"e12708","DOI":"10.1002\/rth2.12708","article-title":"Thrombotic microangiopathies: an illustrated review","volume":"6","author":"Abou\u2010Ismail","year":"2022","journal-title":"Res Pract Thromb Haemost."},{"issue":"8","key":"B70-20250823","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"B71-20250823","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/ndt\/gfaa280","article-title":"Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis","volume":"36","author":"Zhang","year":"2021","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B72-20250823","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bjh.16796","article-title":"Complement as the enabler of carfilzomib\u2010induced thrombotic microangiopathy","volume":"193","author":"Blasco","year":"2021","journal-title":"Br J Haematol."},{"issue":"6","key":"B73-20250823","doi-asserted-by":"crossref","first-page":"E127","DOI":"10.1002\/ajh.23997","article-title":"Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? experience of the French thrombotic microangiopathies reference center: platelet Transfusion in Thrombotic Thrombocytopenic Purpura","volume":"90","author":"Benhamou","year":"2015","journal-title":"Am J Hematol."},{"issue":"4","key":"B74-20250823","first-page":"320","article-title":"Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies","volume":"6","author":"von Baeyer","year":"2002","journal-title":"Therapher Dial."},{"issue":"6","key":"B75-20250823","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med."},{"issue":"3","key":"B76-20250823","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic Apheresis in clinical practice\u2014evidence\u2010based approach from the writing committee of the American Society for Apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher."},{"issue":"5","key":"B77-20250823","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jca.20213","article-title":"Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?","volume":"24","author":"Gore","year":"2009","journal-title":"J Clin Apher."},{"issue":"4","key":"B78-20250823","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol."},{"issue":"1","key":"B79-20250823","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/jth.13882","article-title":"External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment","volume":"16","author":"Li","year":"2018","journal-title":"J Thromb Haemost."},{"issue":"4","key":"B80-20250823","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One."},{"issue":"2","key":"B81-20250823","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ekir.2021.11.009","article-title":"Proteinuria increases the PLASMIC and French scores performance to predict thrombotic thrombocytopenic purpura in patients with thrombotic microangiopathy syndrome","volume":"7","author":"Fage","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B82-20250823","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/trf.16188","article-title":"Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals","volume":"61","author":"Liu","year":"2021","journal-title":"Transfusion."},{"issue":"7","key":"B83-20250823","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1537-2995.2007.01266.x","article-title":"Protein A immunoadsorption therapy for refractory, mitomycin-C-associated thrombotic microangiopathy","volume":"47","author":"Kasper","year":"2007","journal-title":"Transfusion."},{"issue":"5","key":"B84-20250823","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/1097-0142(19930301)71:5<1882::AID-CNCR2820710527>3.0.CO;2-E","article-title":"Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome by protein A immunoadsorption of plasma","volume":"71","author":"Snyder","year":"1993","journal-title":"Cancer."},{"issue":"1","key":"B85-20250823","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00280-008-0900-x","article-title":"Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report","volume":"64","author":"Bharthuar","year":"2009","journal-title":"Cancer Chemother Pharmacol."},{"issue":"5","key":"B86-20250823","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00280-010-1258-4","article-title":"Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome (TTP\/HUS) with rituximab","volume":"65","author":"Gourley","year":"2010","journal-title":"Cancer Chemother Pharmacol."},{"issue":"4","key":"B87-20250823","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.krcp.2015.06.001","article-title":"A case of gemcitabine-induced thrombotic microangiopathy in a urothelial tumor patient with a single kidney","volume":"34","author":"Ryu","year":"2015","journal-title":"Kidney Res Clin Pract."},{"issue":"1","key":"B88-20250823","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000495031","article-title":"Treatment of chemotherapy-induced thrombotic microangiopathy with eculizumab in a patient with metastatic breast cancer","volume":"12","author":"Hausberg","year":"2019","journal-title":"Case Rep Oncol."},{"issue":"23","key":"B89-20250823","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med."},{"issue":"7","key":"B90-20250823","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.21873\/anticanres.14393","article-title":"Rapid improvement in gemcitabine-associated thrombotic microangiopathy after a single dose of eculizumab: case report and review of the literature","volume":"40","author":"Burns","year":"2020","journal-title":"Anticancer Res."},{"issue":"1","key":"B91-20250823","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13256-017-1373-5","article-title":"Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report","volume":"11","author":"Facchini","year":"2017","journal-title":"J Med Case Rep."},{"issue":"1","key":"B92-20250823","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12882-018-0812-x","article-title":"The use of eculizumab in gemcitabine induced thrombotic microangiopathy","volume":"19","author":"Krishnappa","year":"2018","journal-title":"BMC Nephrol."},{"issue":"10","key":"B93-20250823","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.revmed.2015.12.027","article-title":"[Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: a case report]","volume":"37","author":"Rogier","year":"2016","journal-title":"La Revue de M\u00e9decine Interne"},{"issue":"01","key":"B94-20250823","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5414\/CNCS109836","article-title":"Eculizumab in chemotherapy-induced thrombotic microangiopathy","volume":"8","author":"Schulte-Kemna","year":"2020","journal-title":"Clin Nephrol Case Stud."},{"issue":"5","key":"B95-20250823","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ekir.2021.03.001","article-title":"Treatment of gemcitabine-induced thrombotic microangiopathy followed by gemcitabine rechallenge with eculizumab","volume":"6","author":"Efe","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B96-20250823","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12882-021-02470-3","article-title":"Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre","volume":"22","author":"Grall","year":"2021","journal-title":"BMC Nephrol."},{"issue":"6","key":"B97-20250823","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int."},{"issue":"4","key":"B98-20250823","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00467-020-04774-2","article-title":"The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab","volume":"36","author":"Tanaka","year":"2021","journal-title":"Pediatr Nephrol."},{"issue":"7","key":"B99-20250823","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med."},{"issue":"12","key":"B100-20250823","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/13696998.2020.1831519","article-title":"A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome","volume":"23","author":"Wang","year":"2020","journal-title":"J Med Econ."},{"issue":"9","key":"B101-20250823","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40273-020-00929-z","article-title":"Cost-utility analysis of ravulizumab compared with eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria","volume":"38","author":"O\u2019Connell","year":"2020","journal-title":"Pharmacoeconomics."},{"issue":"1","key":"B102-20250823","first-page":"e13031","article-title":"A case of gemcitabine-induced thrombotic microangiopathy treated with ravulizumab in a patient with stage IV pancreatic cancer","volume":"13","author":"MacDougall","year":"2021","journal-title":"Cureus."},{"issue":"1","key":"B103-20250823","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41420-021-00801-9","article-title":"Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells","volume":"8","author":"Park","year":"2022","journal-title":"Cell Death Discov."},{"issue":"3","key":"B104-20250823","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor\u2013dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int."},{"issue":"4","key":"B105-20250823","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med."},{"issue":"5","key":"B106-20250823","doi-asserted-by":"crossref","first-page":"e29641","DOI":"10.1002\/pbc.29641","article-title":"A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high\u2010risk pediatric patients","volume":"69","author":"Higham","year":"2022","journal-title":"Pediatr Blood Cancer."},{"issue":"3","key":"B107-20250823","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0272-6386(99)70194-0","article-title":"Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine","volume":"33","author":"Flombaum","year":"1999","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B108-20250823","doi-asserted-by":"crossref","first-page":"e16.1","DOI":"10.1053\/ajkd.2002.35758","article-title":"Gemcitabine-associated hemolytic-uremic syndrome","volume":"40","author":"Walter","year":"2002","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B109-20250823","first-page":"e119","article-title":"Gemcitabine-associated thrombotic microangiopathy: response to complement inhibition and reinitiation of gemcitabine","volume":"16","author":"Turner","year":"2017","journal-title":"Clin Colorectal Cancer."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000000000061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:00:35Z","timestamp":1786478435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000000000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000000000061","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"2022-10-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}